Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized study of CG001 in paroxysmal nocturnal hemoglobinuria
CTR20261735Phase 2Active
- Sponsor
- Kangjing Biomedical
- Start
- May 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CG001 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Kangjing Biomedical. Started May 2026; status: active.
02
Drugs
CG001
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20261735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261735.